Stilla Technologies SAS (Stilla Technologies) specializes in multiplex digital PCR technology, transforming complex genomic data into actionable insights. The company's primary activities include research and clinical applications in areas such as cancer and liquid biopsy studies, cell and gene therapies, infectious disease detection and food and environmental testing. Stilla Technologies offers a range of digital PCR products, including the Nio+ system, digital PCR kits and assays, digital PCR chips and reagents and digital PCR analysis software. The company's flagship brand is the Crystal Digital PCR solution, featuring the naica system, the industry's first digital PCR system with six fluorescent channels. Stilla Technologies products are used by biomedical researchers and clinicians worldwide. The company operates across the US and France. Stilla Technologies is headquartered in Villejuif, France.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Stilla Technologies SAS
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Table of Contents
- Stilla Technologies SAS Company Overview
- Stilla Technologies SAS Company Snapshot
- Stilla Technologies SAS Pipeline Products and Ongoing Clinical Trials Overview
- Stilla Technologies SAS - Pipeline Analysis Overview
- Stilla Technologies SAS - Key Facts
- Stilla Technologies SAS - Major Products and Services
- Stilla Technologies SAS Pipeline Products by Development Stage
- Stilla Technologies SAS Pipeline Products Overview
- COVID-19 Multiplex Crystal Digital PCR Detection Kit
- COVID-19 Multiplex Crystal Digital PCR Detection Kit Product Overview
- Liquid Biopsy Test - Diabetes
- Liquid Biopsy Test - Diabetes Product Overview
- Liquid Biopsy Test - Infectious Diseases
- Liquid Biopsy Test - Infectious Diseases Product Overview
- Liquid Biopsy Test - Obesity
- Liquid Biopsy Test - Obesity Product Overview
- Liquid Biopsy Test - Oncology
- Liquid Biopsy Test - Oncology Product Overview
- Liquid Biopsy Test - Organ Transplant
- Liquid Biopsy Test - Organ Transplant Product Overview
- Liquid Biopsy Test - Prenatal Screening
- Liquid Biopsy Test - Prenatal Screening Product Overview
- Naica System
- Naica System Product Overview
- Six-Color Naica System
- Six-Color Naica System Product Overview
- Stilla Technologies SAS - Key Competitors
- Stilla Technologies SAS - Key Employees
- Stilla Technologies SAS - Locations And Subsidiaries
- Head Office
- Other Locations & Subsidiaries
- Recent Developments
- Stilla Technologies SAS, Recent Developments
- Mar 31, 2023: Oncological Digital PCR kits to launch after Stilla and Atila cooperation
- Mar 20, 2023: New Stilla Ruby Chip and naica system 21 CFR Part 11 compliance enable full automation of digital PCR testing for clinically-oriented applications
- Apr 07, 2022: TATAA Biocenter expands digital PCR service offering with Stilla’s 6-Color naica system
- Mar 22, 2022: Stilla Technologies expands EMEA footprint with new distribution partnerships
- Oct 20, 2021: Proof of concept SAGAsafe 24-plex ultrasensitive compatibility demonstrated on naica Prism 6 dPCR instrument
- Oct 15, 2021: Leading researchers present 24-Plex digital PCR assay and novel multiplex applications uniquely enabled by Stilla’s 6-Color naica system
- Jul 28, 2021: Stilla launches access program for industry’s first six-color digital PCR system
- Jun 30, 2021: Stilla Technologies Joins Executive Team with Appointment of Matthew Grow, PhD, as Vice President Global Marketing and Commercial Operations
- Mar 03, 2021: Stilla Technologies announced presentation of Naica System at Front line genomics’s webinar
- Feb 03, 2021: Design and optimize high multiplexing digital PCR assays with the naica system
- Appendix
- Methodology
- About the Publisher
- Contact the Publisher
- Disclaimer
- Stilla Technologies SAS Pipeline Products and Ongoing Clinical Trials Overview
- Stilla Technologies SAS Pipeline Products by Equipment Type
- Stilla Technologies SAS Pipeline Products by Indication
- Stilla Technologies SAS, Key Facts
- Stilla Technologies SAS, Major Products and Services
- Stilla Technologies SAS Number of Pipeline Products by Development Stage
- Stilla Technologies SAS Pipeline Products Summary by Development Stage
- COVID-19 Multiplex Crystal Digital PCR Detection Kit - Product Status
- COVID-19 Multiplex Crystal Digital PCR Detection Kit - Product Description
- Liquid Biopsy Test - Diabetes - Product Status
- Liquid Biopsy Test - Diabetes - Product Description
- Liquid Biopsy Test - Infectious Diseases - Product Status
- Liquid Biopsy Test - Infectious Diseases - Product Description
- Liquid Biopsy Test - Obesity - Product Status
- Liquid Biopsy Test - Obesity - Product Description
- Liquid Biopsy Test - Oncology - Product Status
- Liquid Biopsy Test - Oncology - Product Description
- Liquid Biopsy Test - Organ Transplant - Product Status
- Liquid Biopsy Test - Organ Transplant - Product Description
- Liquid Biopsy Test - Prenatal Screening - Product Status
- Liquid Biopsy Test - Prenatal Screening - Product Description
- Naica System - Product Status
- Naica System - Product Description
- Six-Color Naica System - Product Status
- Six-Color Naica System - Product Description
- Stilla Technologies SAS, Key Employees
- Stilla Technologies SAS, Subsidiaries
- Glossary
- Stilla Technologies SAS Pipeline Products by Equipment Type
- Stilla Technologies SAS Pipeline Products by Development Stage
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Medtech SA
- Novacyt SA
- AgCom biotech S.A.R.L.
- DNA Script SAS
- Biomaneo
- Enterome Bioscience SA
- Scipio Bioscience
- IDvet
